Weight loss differences seen between glucagon-like peptide–1 receptor agonists and sodium–glucose cotransporter–2 inhibitors for treatment of type 2 diabetes

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Alan J. Garber, Robert R. Henry, Robert E. Ratner et al. · The Lancet · 2008 · 1K citations

Diabetes Management, Diabetes, Pharmacology +7

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Thomas Blevins, John Pullman, Jaret Malloy et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 442 citations · Full text

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary

Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay et al. · Endocrine Practice · 2017 · 432 citations

Metabolic Syndrome, Diabetes Management, Comprehensive Type 2 +5

American <scp>D</scp>iabetes <scp>A</scp>ssociation <scp>S</scp>tandards of <scp>M</scp>edical <scp>C</scp>are in <scp>D</scp>iabetes 2017

Payal H. Marathe, Helen X. Gao, Kelly L. Close · Journal of Diabetes · 2017 · 427 citations · Full text

Computer Science, Language Documentation

Improved insulin sensitivity after weight loss and exercise training is mediated by a reduction in plasma fatty acid mobilization, not enhanced oxidative capacity

Simon Schenk, Matthew P. Harber, Cara R. Shrivastava et al. · The Journal of Physiology · 2009 · 116 citations · Full text